Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma

Leukemia volume 21, pages 184–187 (2007)Cite this article

We report here the use of naturally occurring non-Hodgkin's lymphoma (NHL) as a model to investigate heritable risk and predictive factors for response in this disease. Dogs are at risk to develop virtually all subtypes of sporadic NHL seen in humans (no transforming lymphotropic viruses such as Epstein–Barr virus or human T-cell leukemia virus type 1 have been conclusively identified in dogs); these tumors not only have morphological similarities between both species, but they also share a similar natural history and clinical behavior1, 2, 3 (Table 1). NHL is the most common life-threatening cancer of dogs, accounting for up to 24% of all malignancies and over 80% of all hematopoietic cancers.1 Untreated cases, especially those of high-grade type, rarely survive beyond 3 months after diagnosis, but the disease is generally responsive to standard of care using CHOP-based chemotherapy protocols, increasing both the length and quality of affected dogs' lives.1 With standard of care, remission can be achieved in >85% of canine NHL cases, and median survival ranges between 9 and 12 months.4, 5 This represents approximately 10% of an average canine lifetime, thus providing a fair target to compare the outcome between dogs and people. Predictive factors for survival in dogs include immunophenotype, clinical substage and histologic subtype. However, as is true for NHL in humans, additional criteria are required to generate more refined schemes that can accurately predict outcomes.

Table 1 Comparison of common NHL subtypes in humans and dogs according to the WHO classificationa
Full size table

Beyond these similarities, peculiar properties of canine NHL increase its value as a model for the human disease. Specifically, the age-adjusted incidence of NHL (excluding other lymphoid neoplasms) is estimated at 107 per 100 000 dog-years,6 a rate approximately five times higher than that reported for humans by the SEER program (∼22 per 100 000).7 In addition, the relative risk for this disease in some breeds is up to four times higher than the average for all dogs,6, 8, 9 suggesting that heritable risk factors for the disease have been firmly established in the derivation of specific breeds.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Hansen K, Khanna C . Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004; 40: 858–880.

    Article  CAS  Google Scholar 

  2. Valli VE, Jacobs RM, Parodi AL, Vernau W, Moore PF . Classification of Hematopoietic Tumors of Domestic Animals, 2nd Series edn. AFIP – American Registry of Pathology: Washington, DC, 2002.

    Google Scholar 

  3. Valli VE, Vernau W, de Lorimier LP, Graham PS, Moore PF . Canine indolent nodular lymphoma. Vet Pathol 2006; 43: 241–256.

    Article  CAS  Google Scholar 

  4. MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM . Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005; 19: 732–736.

    Article  Google Scholar 

  5. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM . Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002; 16: 704–709.

    Article  Google Scholar 

  6. Edwards DS, Henley WE, Harding EF, Dobson JM, Wood JLN . Breed incidence of lymphoma in a UK population of insured dogs. Vet Comp Oncol 2003; 1: 200–206.

    Article  CAS  Google Scholar 

  7. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS . Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265–276.

    Article  CAS  Google Scholar 

  8. Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, Thomas R et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 2005; 65: 5654–5661.

    Article  CAS  Google Scholar 

  9. Priester WA, McKay FW . The occurrence of tumors in domestic animals. Natl Cancer Inst Monogr 1980; 54: 1–210.

    Google Scholar 

  10. Teske E, de Vos JP, Egberink HF, Vos JH . Clustering in canine malignant lymphoma. Vet Q 1994; 16: 134–136.

    Article  CAS  Google Scholar 

  11. Onions DE . A prospective survey of familial canine lymphosarcoma. J Natl Cancer Inst 1984; 72: 909–912.

    CAS  PubMed  Google Scholar 

  12. Thomas R, Smith KC, Ostrander EA, Galibert F, Breen M . Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. Br J Cancer 2003; 89: 1530–1537.

    Article  CAS  Google Scholar 

  13. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M . Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005; 84: 1–12.

    Article  Google Scholar 

  14. Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer 2005; 103: 2091–2098.

    Article  Google Scholar 

  15. Modiano JF, Mayor J, Ball C, Fuentes MK, Linthicum DS . Cdk4 expression and activity are required for cytokine responsiveness in T cells. J Immunol 2000; 165: 6693–6702.

    Article  CAS  Google Scholar 

  16. Gronbaek K, de Nully Brown P, Moller MB, Nedergaard T, Ralfkiaer E, Moller P et al. Concurrent disruption of p16INK4a and the ARF–p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 2000; 14: 1727–1735.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the American Cancer Society, the AKC Canine Health Foundation and the Starlight Fund.

Author information

Authors and Affiliations

  1. University of Colorado Health Sciences Center, Denver, CO, USA

    J F Modiano

  2. North Carolina State University, Raleigh, NC, USA

    M Breen

  3. University of Illinois, Urbana, IL, USA

    V E O Valli

  4. IHC Services, Smithville, TX, USA

    J W Wojcieszyn

  5. University of Alabama at Birmingham, Birmingham, AL, USA

    G R Cutter

Authors
  1. J F Modiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Breen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V E O Valli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J W Wojcieszyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G R Cutter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J F Modiano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Modiano, J., Breen, M., Valli, V. et al. Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma. Leukemia 21, 184–187 (2007). https://doi.org/10.1038/sj.leu.2404392

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404392

This article is cited by

Search

Advanced search

Quick links